Eli Lilly Corp. diskutieren
Eli Lilly Corp.
WKN: 858560 / Symbol: LLY / Name: Eli Lilly / Aktie / Pharmazeutika / Large Cap /
864,70 €
-0,15 %
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Guggenheim from $1,163.00 to $1,161.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at TD Cowen from $960.00 to $1,250.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Morgan Stanley from $1,290.00 to $1,313.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Cantor Fitzgerald from $985.00 to $1,205.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Scotiabank.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,150.00 to $1,300.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Leerink Partners from $1,234.00 to $1,296.00. They now have an "outperform" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Argus from $930.00 to $1,200.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Daiwa Securities Group Inc. from $1,230.00 to $1,250.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $1,350.00 price target on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (LLY) had its "buy" rating reaffirmed by Truist Financial Corporation.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (LLY) had its price target raised by Guggenheim from $1,161.00 to $1,168.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Neueste Beiträge
Needham___Company_LL in Enovis Corp. diskutieren